Work Here?
Overview
VivoSense turns wearable data into digital endpoints to support clinical trials. It cleans and processes raw sensor data and analyzes it to produce auditable insights that measure treatment effects, often through a proprietary cloud platform under service contracts. The company offers end-to-end services from design and data collection to analysis and reporting, not just data collection alone. Its goal is to improve trial accuracy and speed by providing real-time, decision-ready metrics from wearable devices.
About VivoSense
Industries
Data & Analytics
Enterprise Software
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$27M
Headquarters
Newport Beach, California
Founded
2010
Get referred to VivoSense
See people who can refer or advise you
Simplify's Take
What believers are saying
- VivoSense won a NIA/MassAITC grant for Alzheimer’s walking-behavior endpoints.
- MEADOW-AD with Cambridge Cognition validates passive real-world measures in Alzheimer’s.
- VivoSense raised $25 million Series A and has $29 million total funding.
What critics are saying
- VivoSense remains tiny, with about 46-51 employees, limiting enterprise implementation capacity.
- Clinical-trial workflow rivals like Advarra OnCore and Veeva SiteVault commoditize adjacencies.
- If FDA rejects digital endpoints, VivoSense loses its core market.
What makes VivoSense unique
- VivoSense specializes in auditable digital endpoints from wearable sensor data for trials.
- Colin Bower became CEO in 2023, pairing clinical science with commercialization discipline.
- VivoSense positioned itself as the sole Wearable Sensor CRO at SCOPE 2026.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$27M
Above
Industry Average
Funded Over
2 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 3%2 year growth
↑ 0%Max Kopp, a junior high CEO, has secured funding from Crown Wealth LLC and KB Global for Vitasense, a wearable healthcare tech startup. The investment will help refine Vitasense's third-generation prototype, enhance regulatory compliance, and prepare for large-scale clinical testing. Vitasense aims to make its glucose monitoring solution affordable and accessible for diabetic patients. The company has received national recognition, including awards at the National Junior Science and Humanities Symposium.
The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.
VivoSense published a Karger review article, The Case for the Patient-Centric Development of Novel Digital Sleep Assessment Tools in Major Depressive Disorder.
This grant aims to identify outcomes of walking behaviors and physical function that are meaningful to patients with AD.
In collaboration with researchers at the University of Massachusetts Amherst, VivoSense published a new review paper in the Journal of Alzheimer's Disease.
There are no jobs for VivoSense right now.
Find jobs on Simplify and start your career today
About VivoSense
Industries
Data & Analytics
Enterprise Software
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$27M
Headquarters
Newport Beach, California
Founded
2010
There are no jobs for VivoSense right now.
Find jobs on Simplify and start your career today